Identification and Characterization of Circulating Naïve CD4+ and CD8+ T Cells Recognizing Nickel.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 31 05 2018
accepted: 28 05 2019
entrez: 29 6 2019
pubmed: 30 6 2019
medline: 21 10 2020
Statut: epublish

Résumé

Allergic contact dermatitis caused by contact sensitizers is a T-cell-mediated inflammatory skin disease. The most prevalent contact allergens is nickel. Whereas, memory T cells from nickel-allergic patients are well-characterized, little is known concerning nickel-specific naïve T-cell repertoire. The purpose of this study was to identify and quantify naïve CD4+ and CD8+ T cells recognizing nickel in the general population. Using a T-cell priming

Identifiants

pubmed: 31249573
doi: 10.3389/fimmu.2019.01331
pmc: PMC6582854
doi:

Substances chimiques

Nickel 7OV03QG267
Interferon-gamma 82115-62-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1331

Références

Arch Dermatol Res. 1999 May;291(5):247-52
pubmed: 10367706
Clin Exp Immunol. 1999 Aug;117(2):209-16
pubmed: 10444249
Clin Exp Immunol. 1999 Aug;117(2):217-22
pubmed: 10444250
J Immunol. 1999 Sep 1;163(5):2723-31
pubmed: 10453014
Exp Clin Immunogenet. 2000;17(1):42-54
pubmed: 10686482
J Invest Dermatol. 2000 Jul;115(1):81-7
pubmed: 10886512
J Immunol. 2001 Nov 15;167(10):6038-44
pubmed: 11698485
J Exp Med. 2003 Mar 3;197(5):567-74
pubmed: 12615898
J Exp Med. 2003 May 19;197(10):1345-53
pubmed: 12756270
J Immunol. 2003 Dec 1;171(11):5760-8
pubmed: 14634084
J Immunol. 2004 Feb 1;172(3):1926-34
pubmed: 14734778
J Invest Dermatol. 2004 Sep;123(3):494-502
pubmed: 15304089
Toxicology. 2005 Apr 15;209(2):101-7
pubmed: 15767020
Clin Exp Immunol. 2006 Dec;146(3):417-26
pubmed: 17100760
Toxicol Sci. 2007 Oct;99(2):488-501
pubmed: 17636246
J Invest Dermatol. 2008 Aug;128(8):2119-22
pubmed: 18256693
EMBO J. 1991 Jun;10(6):1303-6
pubmed: 2026136
Annu Rev Immunol. 2010;28:275-94
pubmed: 20307209
Expert Rev Clin Immunol. 2005 May;1(1):75-86
pubmed: 20477656
J Immunol. 2010 Jul 1;185(1):89-98
pubmed: 20525893
Immunol Lett. 2010 Sep 6;133(1):42-8
pubmed: 20621124
Toxicol Sci. 2010 Oct;117(2):336-47
pubmed: 20631061
Nat Immunol. 2010 Sep;11(9):814-9
pubmed: 20711192
J Allergy Clin Immunol. 2011 Mar;127(3 Suppl):S74-81
pubmed: 21354503
FASEB J. 2011 Jun;25(6):2040-8
pubmed: 21368101
Contact Dermatitis. 2011 Sep;65 Suppl 1:1-68
pubmed: 21777241
Nat Med. 2011 Sep 18;17(10):1290-7
pubmed: 21926977
Nat Rev Immunol. 2012 Jan 13;12(2):114-24
pubmed: 22240625
Ann Rheum Dis. 2012 Jun;71(6):1088-93
pubmed: 22294635
Toxicol Sci. 2012 May;127(1):150-8
pubmed: 22331489
Toxicol In Vitro. 2013 Apr;27(3):1180-5
pubmed: 22906571
Br J Dermatol. 2013 Apr;168(4):692-9
pubmed: 23383741
Allergy. 2013 Jul;68(7):899-905
pubmed: 23751122
Exp Suppl. 2014;104:89-100
pubmed: 24214620
Exp Suppl. 2014;104:101-14
pubmed: 24214621
J Immunol. 2014 May 15;192(10):4571-80
pubmed: 24719461
Br J Dermatol. 2016 Feb;174(2):319-29
pubmed: 26370659
Toxicol Sci. 2017 Jul 1;158(1):14-22
pubmed: 28472426
Toxicol Appl Pharmacol. 2017 Sep 15;331:69-75
pubmed: 28554661
J Invest Dermatol. 2017 Oct;137(10):2140-2148
pubmed: 28634033
Allergy. 2018 Aug;73(8):1662-1672
pubmed: 29355985
Chem Res Toxicol. 2018 Mar 19;31(3):165-167
pubmed: 29436218
Chem Res Toxicol. 2018 Dec 17;31(12):1323-1331
pubmed: 30421605
Clin Exp Allergy. 2019 May;49(5):636-643
pubmed: 30657219
J Invest Dermatol. 1995 Jul;105(1):92-5
pubmed: 7615984
Contact Dermatitis. 1995 Feb;32(2):65-73
pubmed: 7758323
Immunogenetics. 1994;40(1):27-36
pubmed: 8206523
Eur J Immunol. 1995 Dec;25(12):3308-15
pubmed: 8566016
J Immunol. 1997 Mar 1;158(5):2500-5
pubmed: 9037002
Eur J Immunol. 1997 Aug;27(8):1865-74
pubmed: 9295020
J Invest Dermatol. 1998 Sep;111(3):360-6
pubmed: 9740224
J Invest Dermatol. 1998 Oct;111(4):621-8
pubmed: 9764843

Auteurs

Rami Bechara (R)

Inflammation Chimiokines et Immunopathologie, INSERM, Fac. de Pharmacie-Univ. Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France.

Sabrina Pollastro (S)

ARC Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.

Marie Eliane Azoury (ME)

Inflammation Chimiokines et Immunopathologie, INSERM, Fac. de Pharmacie-Univ. Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France.

Natacha Szely (N)

Inflammation Chimiokines et Immunopathologie, INSERM, Fac. de Pharmacie-Univ. Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France.

Bernard Maillère (B)

CEA, Institut de Biologie et de Technologies, Université Paris-Saclay, Gif-sur-Yvette, France.

Niek de Vries (N)

ARC Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.

Marc Pallardy (M)

Inflammation Chimiokines et Immunopathologie, INSERM, Fac. de Pharmacie-Univ. Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH